Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Subscribe To Our Newsletter & Stay Updated
